Filling unmet demand for critical medicines.
A primary focus on 503b compound & wholesale distribution
Severna Pharmaceuticals operates on the frontlines with hospital directors and buyers to resolve supply chain disruption through careful product selection criteria. Having operated since the inception of FDA 503b, Severna sales representatives are well versed & compliant in regulatory guidance further enhancing your name/brand recognition.
Our Company Values
Proven Go-To-Market strategies with the ability and relationships to make them happen
Severna currently markets FDA regulated 503b Compounds to inpatient Hospital Pharmacies and can work to identify scalable 503b market opportunities with a targeted ROI. With an existing distribution model, Severna Pharmaceuticals can expedite time to market and eliminate sales operations and associated G&A expenditure, while establishing significant revenue across multiple verticals to accelerate growth.
A Little Of Our Story
25 years of experience
Severna Pharmaceuticals currently operates as a Maryland-based Contract Sales Organization (CSO) concentrating on 503b compound & wholesale distribution while pursing FDA 505(b)(2) NDA’s. With executive offices in Annapolis, MD. Severna Pharmaceuticals can expedite time to market and eliminate sales operations & associated G&A expenditure while establishing significant revenue across multiple verticals to accelerate growth. Severna offers immediate access to a seasoned sales team, robust client database & existing relationships within the hospital market as an extension to your existing team.
Years of Experience
Experience true business performance increases
We make it simple to launch and scale your therapy.
Focused on addressing drug shortages and compound supply chain deficiencies, Severna avoids the dual risk factors of clinical development & regulatory approval – since all of its candidates are based on existing, well-known active pharmaceutical ingredients (APIs) with established mechanisms of action, safety profiles, and therapeutic activity. Severna is constantly exploring FDA filing (NDA & ANDA) opportunities for 503b products through strategic partnerships.
As a founding member, Scott’s responsibilities focus on business strategy & business plan execution. Scott currently serves as the Chief Executive Officer of Severna Pharmaceuticals, a pharmaceutical Contract Sales Organization servicing FDA regulated 503B Compounding Facilities & Wholesale Distribution clients. Since founding Severna Pharmaceuticals in 2014, Severna has experienced significant year-over-year growth and is projected to have each of its clients operating at capacity generating $10mm in sales in 2019.
Before founding Severna, Scott served as Executive Vice President of an FDA regulated 503B Outsourcing Facility, Bryce Laboratories, Inc. Scott’s primary focus was to accelerate growth through a concentration of quality assurance, compliance, product control, & industry diversification.
Scott began his career with American Express Financial Advisors, before becoming Area Manager of Operations for AppleOne, Inc., and later Vice President of Business Development & Account Management for BrainBox Enterprises, Inc.
Scott has a Bachelors degree from Hobart College. He and his wife Shannon reside in Annapolis, MD with their two children.
As a founding member, Matt’s responsibilities focus on sales plan development & execution. Matt currently serves as Chief Revenue Officer of Severna Pharmaceuticals, where he is responsible for the day to day sales & performance for Severna clients. In its fifth year, Matt has Severna clients pacing to $10mm in sales in 2018.
Prior to Severna, Matt was the Executive Vice President of Sales for Pharmagen, Inc., a publicly held Pharmaceutical company focused on the nation’s sterile injectable shortage through independent wholesale distribution & pharmaceutical compounding/ADMIX.
Matt was instrumental in growing two pharmaceutical wholesalers, Global Pharmaceutical Sourcing (GPS) and Premium Rx National (PRN). At GPS, Matt developed the sales infrastructure, training program & materials, and compensation plans while recruiting, hiring and training 34 representatives generating $81 million in gross revenue within the first five years of operations. Matt’s success at PRN resulted in generated revenues from zero to $14 million within the first twelve months of operation.
Matt is a graduate of the University of Maryland, College Park, with a Bachelor of Arts in Communications. He and his wife reside in Annapolis, MD with their two children.
Andrew’s responsibilities focus on product selection, vendor qualification, regulatory compliance & governance, and clinical development of FDA products.
Andrew has earned a Doctor of Pharmacy and MBA and was pharmacy manager of one of the country’s first FDA-registered compounding outsourcing facilities. There, Andrew aided in the quality assurance of sterile injectables for a variety of patient populations in the tri-state area. Andrew continued to practice sterile compounding and quality assurance at a subsequent 503A pharmacy before joining Geritrex, an OTC pharmaceutical company as the Director of Regulatory Affairs and Head of Quality. He is a certified quality auditor (CQA) through the American Society for Quality (ASQ).
Andrew currently resides in Clark, NJ with his wife and is a valued member of the community.